World Journal of Urology

, Volume 24, Issue 5, pp 473–480 | Cite as

New imaging modalities in bladder cancer

  • Mansi A. Saksena
  • Douglas M. Dahl
  • Mukesh G. Harisinghani
Topic Paper


  1. 1.
    Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573–1583PubMedCrossRefGoogle Scholar
  3. 3.
    Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC (2002) A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 89:369–373PubMedCrossRefGoogle Scholar
  4. 4.
    Jichlinski P (2003) New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol 13:351–355PubMedCrossRefGoogle Scholar
  5. 5.
    Mallampati GK, Siegelman ES (2004) MR imaging of the bladder. Magn Reson Imaging Clin N Am 12:545–555, viiGoogle Scholar
  6. 6.
    Dobson MJ, Carrington BM, Collins CD et al (2001) The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 56:94–98PubMedCrossRefGoogle Scholar
  7. 7.
    Tekes A, Kamel I, Imam K et al (2005) Dynamic MRI of bladder cancer: Evaluation of staging accuracy. AJR Am J Roentgenol 184:121–127PubMedGoogle Scholar
  8. 8.
    Arslan H, Ceylan K, Harman M, Yilmaz Y, Temizoz O, Can S (2006) Virtual computed tomography cystoscopy in bladder pathologies. Int Braz J Urol 32:147–154; discussion 154Google Scholar
  9. 9.
    Kagadis GC, Siablis D, Liatsikos EN, Petsas T, Nikiforidis GC (2006) Virtual endoscopy of the urinary tract. Asian J Androl 8:31–38PubMedCrossRefGoogle Scholar
  10. 10.
    Braticevici B, Onu M, Bengus F (2006) Virtual cystoscopy–a surgical planning and guidance tool. Arch Ital Urol Androl 78:23–24PubMedGoogle Scholar
  11. 11.
    Browne RF, Murphy SM, Grainger R, Hamilton S (2005) CT cystography and virtual cystoscopy in the assessment of new and recurrent bladder neoplasms. Eur J Radiol 53:147–153PubMedCrossRefGoogle Scholar
  12. 12.
    Tsili AC, Tsampoulas C, Chatziparaskevas N et al (2004) Computed tomographic virtual cystoscopy for the detection of urinary bladder neoplasms. Eur Urol 46:579–585PubMedCrossRefGoogle Scholar
  13. 13.
    Kishore TA, George GK, Bhat S (2006) Virtual cystoscopy by intravesical instillation of dilute contrast medium: preliminary experience. J Urol 175:870–874PubMedCrossRefGoogle Scholar
  14. 14.
    Kawai N, Mimura T, Nagata D, Tozawa K, Kohri K (2004) Intravenous urography-virtual cystoscopy is a better preliminary examination than air virtual cystoscopy. BJU Int 94:832–836PubMedCrossRefGoogle Scholar
  15. 15.
    Yazgan C, Fitoz S, Atasoy C, Turkolmez K, Yagci C, Akyar S (2004) Virtual cystoscopy in the evaluation of bladder tumors. Clin Imaging 28:138–142PubMedCrossRefGoogle Scholar
  16. 16.
    Beer A, Saar B, Rummeny EJ (2003) Tumors of the urinary bladder: technique, current use, and perspectives of MR and CT cystography. Abdom Imaging 28:868–876PubMedCrossRefGoogle Scholar
  17. 17.
    Beer A, Saar B, Zantl N et al (2004) MR cystography for bladder tumor detection. Eur Radiol 14:2311–2319PubMedCrossRefGoogle Scholar
  18. 18.
    Bernhardt TM, Schmidl H, Philipp C, Allhoff EP, Rapp-Bernhardt U (2003) Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report. Eur Radiol 13:305–312PubMedGoogle Scholar
  19. 19.
    Nambirajan T, Sohaib SA, Muller-Pollard C, Reznek R, Chinegwundoh FI (2004) Virtual cystoscopy from computed tomography: a pilot study. BJU Int 94:828–831PubMedCrossRefGoogle Scholar
  20. 20.
    Prando A (2002) CT-virtual endoscopy of the urinary tract. Int Braz J Urol 28:317–322PubMedGoogle Scholar
  21. 21.
    Russell ST, Kawashima A, Vrtiska TJ et al (2005) Three-dimensional CT virtual endoscopy in the detection of simulated tumors in a novel phantom bladder and ureter model. J Endourol 19:188–192PubMedCrossRefGoogle Scholar
  22. 22.
    Kim JK, Park SY, Kim HS, Kim SH, Cho KS (2005) Comparison of virtual cystoscopy, multiplanar reformation, and source CT images with contrast material-filled bladder for detecting lesions. AJR Am J Roentgenol 185:689–696PubMedGoogle Scholar
  23. 23.
    Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF (2002) Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167:1295–1298PubMedCrossRefGoogle Scholar
  24. 24.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMedGoogle Scholar
  25. 25.
    Bajorin DF (2001) Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol 19:17S-20SPubMedGoogle Scholar
  26. 26.
    Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19:4005–4013PubMedGoogle Scholar
  27. 27.
    Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL (1997) Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24:615–620PubMedGoogle Scholar
  28. 28.
    Bachor R, Kotzerke J, Reske SN, Hautmann R (1999) Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 38:46–50PubMedCrossRefGoogle Scholar
  29. 29.
    Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L (2005) FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32:1412–1417PubMedCrossRefGoogle Scholar
  30. 30.
    Hain SF (2005) Positron emission tomography in uro-oncology. Cancer Imaging 5:1–7PubMedGoogle Scholar
  31. 31.
    Machtens S, Boerner AR, Hofmann M, Knapp WH, Jonas U (2004) Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors. Urologe A 43:1397–1409PubMedCrossRefGoogle Scholar
  32. 32.
    Bellin MF, Lebleu L, Meric JB (2003) Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging 28:155–163PubMedCrossRefGoogle Scholar
  33. 33.
    Bellin MF, Roy C, Kinkel K et al (1998) Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles–initial clinical experience. Radiology 207:799–808PubMedGoogle Scholar
  34. 34.
    Harisinghani MG, Barentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499PubMedCrossRefGoogle Scholar
  35. 35.
    Harisinghani MG, Barentsz JO, Hahn PF et al (2002) MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 9(Suppl 2):S312–S313PubMedCrossRefGoogle Scholar
  36. 36.
    Harisinghani MG, Saini S, Hahn PF, Weissleder R, Mueller PR (1998) MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (combidex). Acad Radiol 5(Suppl 1):S167–S169, discussion S183–S184Google Scholar
  37. 37.
    Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175:494–498PubMedGoogle Scholar
  38. 38.
    Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175:489–493PubMedGoogle Scholar
  39. 39.
    Koenig SH, Kellar KE (1995) Theory of 1/T1 and 1/T2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med 34:227–233PubMedGoogle Scholar
  40. 40.
    Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G (1994) MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am J Roentgenol 162:201–207PubMedGoogle Scholar
  41. 41.
    Clement O, Guimaraes R, de Kerviler E, Frija G (1994) Magnetic resonance lymphography. Enhancement patterns using superparamagnetic nanoparticles. Invest Radiol 29(Suppl 2):S226–S228PubMedCrossRefGoogle Scholar
  42. 42.
    Anzai Y, Piccoli CW, Outwater EK et al (2003) Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 28:777–788Google Scholar
  43. 43.
    Hudgins PA, Anzai Y, Morris MR, Lucas MA (2002) Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 23:649–656PubMedGoogle Scholar
  44. 44.
    Harisinghani MG, Dixon WT, Saksena MA et al (2004) MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics 24:867–878PubMedGoogle Scholar
  45. 45.
    Deserno WM, Harisinghani MG, Taupitz M et al (2004) Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233:449–456PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Mansi A. Saksena
    • 1
  • Douglas M. Dahl
    • 2
  • Mukesh G. Harisinghani
    • 1
  1. 1.Division of Abdominal Imaging and Intervention, Department of RadiologyMassachusetts General HospitalBostonUSA
  2. 2.Department of UrologyMassachusetts General HospitalBostonUSA

Personalised recommendations